Inflammatory Bowel Disease

Featured Article
Best practice statements help to guide decision-making in diagnosis, surveillance, and treatment of ulcerative colitis and Crohn disease among patients aged 60 years and older.
Clearly communicating the findings of endoscopy to pathologists, colleagues, and patients requires some standardization in the preparation of endoscopic reports, David T. Rubin, MD, told the attendees of the Advances in Inflammatory Bowel Diseases 2020 virtual meeting on December 11.
Updates to the SECURE-IBD international registry indicate that thiopurines and combination therapies may place patients with inflammatory bowel disease at heightened risk of poor outcomes from COVID-19, while anti-tumor necrosis factor agents may be protective.
Laurent Peyrin-Biroulet, MD, from the University of Nancy, France, spoke to the Advances in Inflammatory Bowel Diseases 2020 virtual meeting about surveillance, prevention, and treatment of cancer among patients with inflammatory bowel disease.
With many agents to choose from and even more slated for the near future, how do you choose the best therapy for your patients with inflammatory bowel disease? William Sandborn, MD, delved into the subject at the Advances in Inflammatory Bowel Diseases 2020 virtual meeting.
Aside from formal measurements of disease activity, there are still some practical approaches to assessing inflammatory bowel disease that can be helpful for clinicians, according to a presentation by Bruce Sands, MD, at the Advances in Inflammatory Bowel Disease 2020 virtual meeting.
In an oral presentation honored as Best In Category (IBD) at the American College of Gastroenterology 2020 Clinical Meeting and Postgraduate Course, Lauri Keefer, PhD, of the Icahn School of Medicine at Mount Sinai in New York City, shows how the ability to ‘bounce back’ from challenges improves outcomes and reduces health care utilization for patients with inflammatory bowel disease. 
The human leukocyte antigen variant that causes patients to develop antibodies to anti-tumor necrosis factor therapeutics is fairly common in patients of European and Hispanic descent, but seems not to cause immunogenicity to other biologics, according to research presented American College of Gastroenterology (ACG) 2020 clinical meeting and postgraduate course.
Sunanda V. Kane, MD, FACG, from the Mayo Clinic, reviewed the growing number of therapeutic agents for the treatment of inflammatory bowel disease, and how to best choose and position them for optimum outcomes, during her talk at the ACG2020 Virtual clinical meeting and postgraduate course.
Patients with inflammatory bowel disease have historically had lower rates of vaccination than the general population. Tell us how you manage immunizations for your patients with IBD by taking our quick poll.
Symptoms of irritable bowel syndrome occur with some frequency in patients already diagnosed with inflammatory bowel disease. Kerri Glassner, DO, explained the best way to approach diagnosing and treating these patients at the September 26 virtual Advances in Inflammatory Bowel Disease 2020 regional meeting.